Adium Pharma S.A. Sustainability Profile
Adium Pharma S.A., a prominent player in the pharmaceutical industry, is headquartered in Uruguay (UY) and operates extensively across Latin America. Founded in 2006, the company has established itself as a leader in the development and manufacturing of high-quality generic and specialty pharmaceuticals. Adium Pharma is renowned for its innovative approach to drug formulation, particularly in the areas of oncology, infectious diseases, and central nervous system disorders. The company’s commitment to quality and compliance has earned it a strong market position, with notable achievements in regulatory approvals and product launches. With a focus on enhancing patient outcomes, Adium Pharma continues to expand its portfolio, offering unique solutions that address unmet medical needs in the region.
DitchCarbon Score
How does Adium Pharma S.A.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Retail Trade Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Adium Pharma S.A.'s score of 26 is lower than 55% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Adium Pharma S.A.'s reported carbon emissions
Adium Pharma S.A., headquartered in Uruguay (UY), currently does not report any carbon emissions data, as indicated by the absence of specific figures in kg CO2e. Furthermore, the company has not established any documented reduction targets or climate pledges, which suggests a lack of formal commitments to address carbon emissions at this time. In the context of the pharmaceutical industry, where sustainability and climate action are increasingly critical, Adium Pharma S.A. may need to consider developing a comprehensive strategy to measure and reduce its carbon footprint. This could involve setting science-based targets and participating in initiatives such as the Science Based Targets initiative (SBTi) to align with global climate goals. As of now, without any emissions data or reduction initiatives, Adium Pharma S.A. appears to have opportunities for improvement in its climate commitments and sustainability practices.
How Carbon Intensive is Adium Pharma S.A.'s Industry?
How Carbon Intensive is Adium Pharma S.A.'s Location?
Adium Pharma S.A.'s Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Adium Pharma S.A. has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
